Efficacy of immunotherapy in ARID1A-mutant solid tumors: a single-center retrospective study
Discover Oncology · 07.06.2024 · 15 (1)
DOI: 10.1007/s12672-024-01074-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Discover Oncology, online erschienen am 07.06.2024. Verfasst von Hai Zhou und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The Affiliated Hospital of Qingdao University, No. 7 Jiaxing Road, Qingdao, 266000, Shandong, China. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Shandong Province, Special Funding for Qilu Sanitation and Health Leading Talents Cultivation Project.
Abstract (Originalsprache)
Background
Immune checkpoint inhibitors (ICIs), especially those targeting programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1), have introduced a new treatment landscape for many types of tumors. However, they only achieve a limited therapeutic response. Hence, identifying patients who may benefit from ICIs is currently a challenge.
Methods
47 tumor patients harboring ARID1A mutations were retrospectively studied. The genomic profiling data through next-generation sequencing (NGS) and relevant clinical information were collected and analyzed. Additionally, bioinformatics analysis of the expression of immune checkpoints and immune cell infiltration levels was conducted in ARID1A -mutant gastric cancer (GC).
Results
ARID1A mutations frequently co-occur with mutations in DNA damage repair (DDR)-associated genes. Among the 35 ARID1A -mutant patients who received immunotherapy, 27 were evaluable., with the objective response rate (ORR) was 48.15% (13/27), and the disease control rate (DCR) was 92.59% (25/27). Moreover, survival assays revealed that ARID1A -mutant patients had longer median overall survival (mOS) after immunotherapy. In ARID1A -mutated GC patients, receiving ICIs treatment indicated longer progressive-free survival (PFS). Additionally, the incidence of microsatellite instability-high (MSI-H), high tumor mutation burden (TMB-H) and Epstein‒Barr virus (EBV) infection was elevated. Bioinformatic analysis showed significant enrichment of immune response and T cell activation pathway within differentially expressed genes in ARID1A -mutant GC group. Finally, ARID1A mutations status was considered to be highly correlated with the level of tumor infiltrating lymphocytes (TILs) and high expression of immune checkpoints.
Conclusions
Patients with tumors harboring ARID1A mutations may achieve better clinical outcomes from immunotherapy, especially in GC. ARID1A mutations can lead to genomic instability and reshape the tumor immune microenvironment (TIME), which can be used as a biomarker for immunotherapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology, The Affiliated Hospital of Qingdao University, No. 7 Jiaxing Road, Qingdao, 266000, Shandong, China.
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
- Precision Medicine Center of Oncology, The Affiliated Hospital of Qingdao University, Qingdao, 266000, Shandong, China.
- Medical College of Qingdao University, No.308 Ningxia Road, Qingdao, 266000, Shandong, China.
- Department of Oncology, The Affiliated Hospital of Qingdao University, No. 7 Jiaxing Road, Qingdao, 266000, Shandong, China. houheleihhl@163.com.
Förderung
- Natural Science Foundation of Shandong Province
- Special Funding for Qilu Sanitation and Health Leading Talents Cultivation Project
Zitieren
APA
Zhou, H., Sun, D., Song, S., Niu, Y., Zhang, Y., Lan, H., Cui, J., Liu, H., Liu, N., & Hou, H. (2024). Efficacy of immunotherapy in ARID1A-mutant solid tumors: a single-center retrospective study. Discover Oncology, 15(1). https://doi.org/10.1007/s12672-024-01074-1
Vancouver
Zhou H, Sun D, Song S, Niu Y, Zhang Y, Lan H, et al. Efficacy of immunotherapy in ARID1A-mutant solid tumors: a single-center retrospective study. Discover Oncology. 2024;15(1). doi:10.1007/s12672-024-01074-1
BibTeX
@article{Zhou2024,
author = {Zhou, Hai and Sun, Dantong and Song, Shanai and Niu, Yurong and Zhang, Yuming and Lan, Hongwei and Cui, Jiali and Liu, Houde and Liu, Ning and Hou, Helei},
title = {Efficacy of immunotherapy in ARID1A-mutant solid tumors: a single-center retrospective study},
journal = {Discover Oncology},
year = {2024},
volume = {15},
number = {1},
doi = {10.1007/s12672-024-01074-1}
}
EUVIMED